Delta-Fly Pharm
Delta-Fly Pharma develops new, affordable anticancer drugs with improved safety and efficacy using existing compounds, aiming to reduce side effects and alleviate the economic burden on patients and governments.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | N/A | IPO |
| Total Funding | 000k | ||
| JPY | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 200 % | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1550 %) | (286 %) | (321 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1556 %) | (288 %) | (322 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1398 % | 289 % | 314 % | - | - |
Source: Company filings or news article
Related Content
Delta-Fly Pharma, Inc. is a biopharmaceutical company specializing in the development of innovative oncology treatments, particularly for hematologic malignancies such as acute myeloid leukemia (AML). The company operates in the highly competitive pharmaceutical market, focusing on the research and development of novel drug candidates that address unmet medical needs. Delta-Fly Pharma primarily serves healthcare providers, hospitals, and research institutions that require advanced therapeutic solutions for cancer treatment.
The company's business model revolves around the discovery, clinical development, and commercialization of its proprietary drug candidates. Revenue is generated through a combination of licensing agreements, partnerships with larger pharmaceutical companies, and direct sales of its approved therapies. Delta-Fly Pharma's strategic approach includes conducting rigorous clinical trials to ensure the safety and efficacy of its products, thereby gaining regulatory approvals and market acceptance.
Key products in the pipeline include DFP-10917, which has shown promising results in Phase I/II studies for relapsed/refractory AML, and other compounds targeting various cancer types. The company leverages its scientific expertise and collaborative partnerships to accelerate the development process and bring effective treatments to market.
Keywords: oncology, hematologic malignancies, acute myeloid leukemia, biopharmaceutical, drug development, clinical trials, cancer treatment, innovative therapies, regulatory approvals, healthcare providers.